Stockhouse.com uses cookies on this site. By continuing to use our service, you agree to our use of cookies. Cookies are used to offer you a better browsing experience and to analyze our traffic. We also use them to share usage information with our partners. See full details.
I Agree
×
Join today and have your say! It’s FREE!

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Please Try Again
{{ error }}
By providing my email, I consent to receiving investment related electronic messages from Stockhouse.

or

Privacy Policy | Disclaimer

Sign In

Please Try Again
{{ error }}
Password Hint : {{passwordHint}}
Forgot Password?

or

Privacy Policy | Disclaimer
Please Try Again {{ error }}

Send my password

Return to Login
SUCCESS
An email was sent with password retrieval instructions. Please go to the link in the email message to retrieve your password.

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Quote  |  Bullboard  |  News  |  Opinion  |  Profile  |  Peers  |  Filings  |  Financials  |  Options  |  Price History  |  Ratios  |  Ownership  |  Insiders  |  Valuation

Stock Quote Today & Recent News Ionis Pharmaceuticals Inc IONS

Healthcare Biotechnology
Ionis Pharmaceuticals, Inc. is engaged in ribonucleic acid (RNA)-targeted therapeutics. The Company has five marketed medicines and a pipeline in neurology, cardiology, and other areas of high patient need. It has nine medicines in Phase III development and multiple additional medicines in early and mid-stage development. The Company’s products include SPINRAZA, QALSODY, WAINUA, TEGSEDI and... see more
{{currentVideo.companyName}}
{{currentVideo.intervieweeName}}{{currentVideo.intervieweeTitle}}
{{currentVideo.headline}}
{{currentVideo.link1Text}}
{{currentVideo.link2Text}}
< Previous
{{moreVideoText}}
Next >

Current News (NDAQ:IONS)

Ionis to present at upcoming investor conferences

PR Newswire November 7, 2024

Ionis Announces Pivotal Phase 3 Trial Design for ION582 in Angelman Syndrome

PR Newswire November 6, 2024

Ionis reports third quarter 2024 financial results

PR Newswire November 6, 2024

Ionis announces FDA acceptance of New Drug Application for donidalorsen for prophylactic treatment of HAE

PR Newswire November 4, 2024

Ionis to hold third quarter 2024 financial results webcast

PR Newswire October 23, 2024

WAINZUA (eplontersen) recommended for approval in the EU by CHMP for the treatment of adults with polyneuropathy associated with hereditary transthyretin-mediated amyloidosis

PR Newswire October 21, 2024

New Higher Dose Nusinersen Efficacy and Safety Data Presented at World Muscle Society Congress, Highlight Potential to Maximize Benefit of Nusinersen in SMA

GlobeNewswire October 8, 2024

New positive donidalorsen data to be presented at 2024 American College of Allergy, Asthma & Immunology (ACAAI) Annual Scientific Meeting

PR Newswire October 3, 2024

Zilganersen granted U.S. FDA Fast Track designation for people living with Alexander disease

PR Newswire October 1, 2024
View More News ››

Opinion & Analysis (NDAQ:IONS)

Small-Cap Growth ETFs Restore Leadership Role

Benzinga.com  March 19, 2015

Biotech Stocks Sell Off, ETFs Fall Over 5%

Benzinga.com  December 23, 2014

3 Biotech ETFs Rally On Merger News

Benzinga.com  December 8, 2014

Turkey ETF in Focus on Political Worries - ETF News And Commentary

Benzinga.com  July 16, 2014

Will Gold ETFs Continue To Shine? - ETF News And Commentary

Benzinga.com  June 18, 2014
View More Opinion ››

Bullboard Posts (NDAQ:IONS)

New data from the Phase 3 NEURO-TTRansform study evaluating

NEWS: $IONS New data from the Phase 3 NEURO-TTRansform study evaluating WAINUA(TM) (eplontersen) to be presented at the 2024...
whytestocks - May 23, 2024

VP exercised options

A vice president of Isis Pharmaceuticals Inc. exercised options for 12,200 shares of common stock and sold them under a prearranged...
mart33 - April 10, 2008

news and potential uptrend

 Isis Pharmaceuticals last week reported a sharp drop in its net loss for 2007 despite higher operating expenses as the company...
mart33 - March 24, 2008

Overview of the stock

Here are some points to consider:1) Biotech industry is very volatile though ISIS stock prices started accelerating upwards in August and...
bearsko - February 25, 2008

isis needs a kiss of life

Maybe Tobin is the volunteer...trading on the 27th April,07 @ $10.22
kungfu010 - April 27, 2007

Tobin Smith is pumping ISIS presently

Wow, I can't believe that no one has left a message on this board since 2003. Toby Smith (Tobin) is calling this one a major buy-out...
Silver_Is_Money - February 4, 2007
View more Bullboard ››

Freegold Ventures Limited

Freegold Ventures Limited

Freegold Ventures Limited is a Canada-based company focused on exploration in Alaska. The Company holds Golden Summit Gold ...
View More »